Faricimab Loading Phase Shows Promising Results in Visual Outcomes and Structural Improvement in Diabetic Macular Edema

Strategic Insights -

Research from Agostino Gemelli University Hospital in Rome, Italy, has shed light on the effects of a faricimab loading phase on diabetic macular edema. The study, which evaluated 46 eyes with resistant diabetic macular edema, found significant improvements in visual acuity and anatomic outcomes. The findings suggest that faricimab could be a viable treatment option for this condition.

Key Takeaways:

  • The study found a significant improvement in best-corrected visual acuity from baseline to the fourth follow-up examination (0.55 +/- 0.42 vs. 0.36 +/- 0.30 logMAR; P = 0.03).
  • Sixty-five percent of eyes showed visual improvement during follow-up, whereas 91% showed anatomic improvement, with a mean central macular thickness reduction of 108.4 mu m (P = 0.0002).
  • The study also found a reduction in the prevalence of hyperreflective foci from 87% at baseline to 24% at the fourth follow-up (P = 0.0005).
  • Disorganization of inner retina layers was reported in eight eyes at baseline and resolved in three eyes.
  • The study concluded that faricimab loading phase showed promising results in visual outcomes and structural improvement in resistant diabetic macular edema.

Statistics:

  • 46 eyes with diabetic macular edema were evaluated in the study.
  • 65% of eyes showed visual improvement during follow-up.
  • 91% of eyes showed anatomic improvement, with a mean central macular thickness reduction of 108.4 mu m.
  • The prevalence of hyperreflective foci reduced from 87% at baseline to 24% at the fourth follow-up.
  • Best-corrected visual acuity significantly improved from baseline to the fourth follow-up by 0.55 +/- 0.42 vs. 0.36 +/- 0.30 logMAR.

Sources:

  • Effects of Faricimab Loading Phase On Diabetic Macular Edema In Real-world Setting. Retina-the Journal of Retinal and Vitreous Diseases, 2025;45(7):1313-1322.
  • Agostino Gemelli University Hospital. Department of Ophthalmology. Institute for Cancer Research and Treatment (IRCCS).